Microglia in Alzheimer's disease represent the brain's innate immune cells that play a dual role in AD pathogenesis — both promoting neuroinflammation that drives neurodegeneration and attempting to clear toxic amyloid deposits. Understanding microglial function is critical for developing disease-modifying therapies for Alzheimer's disease.
Microglia are the resident macrophage cells of the central nervous system (CNS), originating from yolk sac progenitors during embryonic development. In Alzheimer's disease, microglia become persistently activated in response to amyloid-beta (Aβ) plaques and neurofibrillary tangles, adopting a disease-associated microglia (DAM) phenotype.
Key aspects of microglial involvement in AD:
- Amyloid clearance: Attempting to phagocytose and clear Aβ deposits
- Neuroinflammation: Producing pro-inflammatory cytokines that contribute to neuronal damage
- Plaque maintenance: Forming a protective barrier around amyloid plaques
- Synaptic pruning: Eliminating synapses in an aberrant manner
- Trophic support: Attempting to provide neurotrophic factors to neurons
Microglia recognize Aβ through multiple pattern recognition receptors:
-
TLRs (Toll-like receptors):
- TLR2: Recognizes Aβ fibrils
- TLR4: Activated by Aβ
- TLR6: Co-receptor with TLR2
-
Scavenger receptors:
- SR-A1: Class A scavenger receptor
- CD36: Forms complex with TLR4/TLR6
- RAGE: Receptor for advanced glycation end products
-
Complement receptors:
- CR3 (CD11b/CD18): Mediates complement-dependent phagocytosis
- C1q: Initiates complement cascade
Aβ-activated microglia trigger inflammatory cascades:
- NF-κB pathway: Major driver of pro-inflammatory gene expression
- MAPK pathways: ERK, JNK, and p38 signaling
- Inflammasome activation: NLRP3 inflammasome formation
- JAK/STAT signaling: Cytokine-mediated transcription
Activated microglia produce:
-
Pro-inflammatory:
- IL-1β: Promotes neuroinflammation
- IL-6: Acute phase response
- TNF-α: Cytotoxic effects
- IL-18: IFN-γ stimulating
-
Anti-inflammatory:
- IL-10: Anti-inflammatory
- TGF-β: Immunomodulation
- IL-4: M2 polarization
- IL-13: Anti-inflammatory
Microglia transition through stages in AD:
Stage 1 - Homeostatic microglia:
- Express homeostatic markers (P2RY12, CX3CR1)
- Surveillance function
- Process monitoring
Stage 2 - Early DAM:
- Upregulation of ApoE
- TREM2-independent activation
- Early inflammatory response
Stage 3 - Fully activated DAM:
- Upregulation of TREM2
- Lipid metabolism genes (APOE, CD36)
- Phagocytic activation
- Cytokine production
TREM2 is critical for microglial responses in AD:
- TREM2 variants increase AD risk (R47H, R62H)
- TREM2 activation triggers:
- DAP12 phosphorylation
- Syk kinase activation
- Phagocytosis enhancement
- Metabolic reprogramming
- TREM2 deficiency leads to:
- Impaired Aβ clearance
- Reduced plaque compaction
- Increased neuritic damage
Microglia attempt to clear Aβ through:
-
Receptor-mediated phagocytosis:
- TREM2-DAP12 signaling
- Complement-mediated clearance
- Scavenger receptor uptake
-
Enzymatic degradation:
-
Aβ export:
- Perivascular drainage
- Glymphatic clearance
Microglia surround amyloid plaques:
- Form a protective barrier
- Limit plaque spread
- Attempt continuous phagocytosis
- Become a source of chronic inflammation
Microglia contribute to tau pathology propagation:
- Tau uptake: Internalize extracellular tau
- Tau processing: May modify tau through proteases
- Tau spread: Propagate tau to connected neurons
- Inflammation exacerbation: Tau stimulates additional inflammation
Tau pathology activates microglia through:
- TLR recognition of tau
- Neuronal debris from tau-affected neurons
- Astrocyte cross-talk
- Complement activation
Sustained microglial activation contributes to:
-
Synaptic loss:
- Complement-mediated pruning
- Excessive phagocytosis
- Impaired synaptic function
-
Neuronal death:
- Cytotoxicity from cytokines
- Oxidative stress
- Excitotoxicity
-
Network dysfunction:
- Circuit-level disruption
- Synchronization abnormalities
- Oscillation impairments
CSF and plasma markers of microglial activation:
- YKL-40 (chitinase-3-like protein 1)
- sTREM2 (soluble TREM2)
- IL-1β (interleukin-1 beta)
- TNF-α (tumor necrosis factor alpha)
- GFAP (glial fibrillary acidic protein)
-
Anti-inflammatory approaches:
- NSAIDs: Reduce microglial activation (mixed results in trials)
- Minocycline: Antibiotic with anti-inflammatory effects
- Colchicine: Microtubule inhibitor
-
TREM2-targeting:
- TREM2 agonistic antibodies
- TREM2 activation enhancement
- TREM2 upstream modulators
-
CSF1R inhibition:
- Prevent microglial proliferation
- Reduce disease burden
- PLX3397, PLX5622
-
Phagocytosis modulation:
- Enhance Aβ clearance
- Reduce inflammation
- CD33 inhibition
- Balancing protective vs. harmful functions
- Timing of intervention
- Peripheral vs. CNS effects
- Heterogeneity of microglial states
Microglial research utilizes:
- APP/PS1 mice: Amyloid model
- Tauopathy models: Tau pathology
- 5xFAD mice: Aggressive amyloid model
- TREM2 knock-in/knockout: Genetic studies
- iPSC-derived microglia: Human modeling
Studies employ:
- Single-cell RNA-seq: Microglial heterogeneity
- Spatial transcriptomics: Location-specific changes
- Flow cytometry: Cell surface markers
- Live imaging: Two-photon microscopy
- Electrophysiology: Neuron-microglia interactions